Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$136 million dollars loss for 6 month STRONG SELL-SELL-SELL =
COMMUNIST CHINA DEFRAUDING AMERICAN INVESTORS IN ORDER TO DOMINATE YOU.
DO NOT BUY CHINES STOCKS AND PRODUCTS
=REMEMBER THIS COMPANY LiNiu Technology Group (LINU)JUST CREATED ON THE MONEY WHICH WAS TAKEN BY SELLING ILLEGAL DRAGS = WOMAN AND CHILDREN SLAVERY.
About $200 million chines people getting pay for their work for year , just thing what is for chines company loss $136 million for just 6 month for what?
IN 2 WEEKS LINU SHARES WILL BE WORTHLESS .
STRONG SELL-SELL-SELL =COMMUNIST CHINA DEFRAUDING AMERICAN INVESTORS
IN ORDER TO DOMINATE YOU. DO NOT BUY CHINES STOCKS AND PRODUCTS =REMEMBER THIS COMPANY LiNiu Technology Group (LINU)JUST CREATED ON THE MONEY WHICH WAS TAKEN BY SELLING ILLEGAL DRAGS = WOMAN AND CHILDREN SLAVERY.
IN TO WEEKS LINU SHARES WILL BE WORTHLESS .
STRONG SELL-SELL-SELL =COMMUNIST CHINA DEFROCKING AMERICAN INVESTORS
IN ORDER TO DOMINATE YOU. DO NOT BUY CHINES STOCKS AND PRODUCTS =REMEMBER THIS COMPANY LiNiu Technology Group (LINU)JUST CRATED ON MONEY WHICH WAS TAKEN BY SELLING ILLEGAL DRAGS AND CHILDREN AND WOMAN SLAVERY.
IN TO WEEKS LINU SHARES WAIL BE WORTHLESS .
BUY NEWS ALERT-ANALYST UPGRADE SHARE PRICE TO $3 during 52 weeks. Its minimum price target.
(NASDAQ:MNGA) reported $-0.2 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.4 by $0.2 with surprise factor of 50%.
A large surprise factor in either direction typically can lead to a significant swing in the stock price in the hours and days after the report. Previously Magnegas Corporation
https://postregistrar.com/2017/12/01/under-analysts-radar-magnegas-corporation-mnga-2/
TIME TO BUY AND GET REACH 90% GAIN IN ANY TIME
MagneGas (NASDAQ:MNGA) shares are up 4% following the news.
"We have already booked $3.5M in gasification unit sales in October and we are on pace to dramatically increase metal cutting fuel and welding supply revenues in the fourth quarter of 2017. As a result, we are on track to generate more revenue in the fourth quarter of 2017 alone, than in any full fiscal year in our corporate history."
https://seekingalpha.com/news/3312529-magnegas-provides-business-update
TIME TO BUY -$VTGN Key Stocks To Watch- VistaGen Therapeutics (NASDAQ:VTGN) on Nov. 29
http://quad7capital.com/2017/11/25/key-stocks-watch-week-2/
$VTGN Key Stocks To Watch- VistaGen Therapeutics (NASDAQ:VTGN) on Nov. 29
http://quad7capital.com/2017/11/25/key-stocks-watch-week-2/
NEWS-Sphera Funds Management LTD. Has $1.69 Million Holdings in VistaGen Therapeutics, Inc. (VTGN)
Sphera Funds Management LTD. raised its holdings in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) by 94.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 1,058,386 shares of the company’s stock after acquiring an additional 514,286 shares during the period. Sphera Funds Management LTD. owned 9.08% of VistaGen Therapeutics worth $1,693,000 at the end of the most recent reporting period.
Separately, D.A. Davidson & CO. raised its holdings in VistaGen Therapeutics by 8.2% in the 2nd quarter. D.A. Davidson & CO. now owns 98,500 shares of the company’s stock valued at $184,000 after acquiring an additional 7,500 shares during the last quarter. 15.15% of the stock is currently owned by hedge funds and other institutional investors.
VistaGen Therapeutics, Inc. (VTGN) opened at $0.86 on Friday. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of -0.01. VistaGen Therapeutics, Inc. has a twelve month low of $0.75 and a twelve month high of $4.08.
VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.05). equities research analysts predict that VistaGen Therapeutics, Inc. will post -1.99 EPS for the current fiscal year.
https://ledgergazette.com/2017/11/24/sphera-funds-management-ltd-has-1-69-million-holdings-in-vistagen-therapeutics-inc-vtgn.html
BUY ALERT NEWS VistaGen Receives in Germany England New European Patent for AV-101 Treatment for Depression.
https://www.newsquantified.com/stock-report/vtgn-vistagen-therapeutics-receives-european-patent-for-av101-04u4j8
BUY ALERT NEWS VistaGen Receives in Germany England New European Patent for AV-101 Treatment for Depression.
https://www.newsquantified.com/stock-report/vtgn-vistagen-therapeutics-receives-european-patent-for-av101-04u4j8
$VTGN BUY ALERT NEWS VistaGen Receives in Germany England New European Patent for AV-101 Treatment for Depression.
https://www.newsquantified.com/stock-report/vtgn-vistagen-therapeutics-receives-european-patent-for-av101-04u4j8
$INPX TIME TO ADD MORE SHARES BUY-BUY-BUY!
Q3 2017 Business Highlights and Recent Developments
Inpixon announced a partnership with GTRI, an innovator in IT consulting and services, to render comprehensive three-dimensional physical cybersecurity solutions, including the Inpixon Indoor Positioning Analytics (IPA) Security Dome for physical premises, airwaves and wireless devices.
Inpixon completed a financial agreement with Payplant LLC (“Payplant”). The Payplant facility will allow increased flexibility in meeting working capital needs by allowing Inpixon to process more commercial and government purchase orders.
Inpixon’s subsidiary, Inpixon Federal, received two delivery orders from the Bureau of Census totaling $1.4 million.
Inpixon joined the ngConnect Program to advance the adoption and development of Indoor Positioning Analytics and collaborate with the multi-industry open innovation ecosystem founded by Nokia, providing an indoor positioning and analytics platform for next generation networks, cloud and IoT technologies.
Inpixon signed a technology refresh deal with a leading beverage distributor for $750K for Q2 and Q3 and will upgrade the customer’s existing infrastructure.
Inpixon Federal expanded its offering of RadPRO SecurPASS Security Screening System, partnering with Virtual Imaging, Inc., a wholly owned subsidiary of Canon U.S.A., Inc., to improve the safety and security of federal, state and local government correctional facilities, who has delivered over 100 RadPRO SecurPASS Security Screening Systems across the nation’s correctional facilities.
Inpixon Federal anticipates over $5.5 million in revenue from this product line by the end of 2017.
Inpixon approved to expand its NASA Solutions for Enterprise-Wide Procurement V (SEWP V) catalog to include offerings that meet the requirements for the Government-wide Strategic Solutions (GSS) for laptops and monitors.
Inpixon won the 2017 IoT Security Excellence Award.
$INPX TIME TO ADD MORE SHARES =NEVER HAD R/S BEFORE =NO R/S IN NEAR FUTURE
Q3 2017 Business Highlights and Recent Developments
Inpixon announced a partnership with GTRI, an innovator in IT consulting and services, to render comprehensive three-dimensional physical cybersecurity solutions, including the Inpixon Indoor Positioning Analytics (IPA) Security Dome for physical premises, airwaves and wireless devices.
Inpixon completed a financial agreement with Payplant LLC (“Payplant”). The Payplant facility will allow increased flexibility in meeting working capital needs by allowing Inpixon to process more commercial and government purchase orders.
Inpixon’s subsidiary, Inpixon Federal, received two delivery orders from the Bureau of Census totaling $1.4 million.
Inpixon joined the ngConnect Program to advance the adoption and development of Indoor Positioning Analytics and collaborate with the multi-industry open innovation ecosystem founded by Nokia, providing an indoor positioning and analytics platform for next generation networks, cloud and IoT technologies.
Inpixon signed a technology refresh deal with a leading beverage distributor for $750K for Q2 and Q3 and will upgrade the customer’s existing infrastructure.
Inpixon Federal expanded its offering of RadPRO SecurPASS Security Screening System, partnering with Virtual Imaging, Inc., a wholly owned subsidiary of Canon U.S.A., Inc., to improve the safety and security of federal, state and local government correctional facilities, who has delivered over 100 RadPRO SecurPASS Security Screening Systems across the nation’s correctional facilities. Inpixon Federal anticipates over $5.5 million in revenue from this product line by the end of 2017.
Inpixon approved to expand its NASA Solutions for Enterprise-Wide Procurement V (SEWP V) catalog to include offerings that meet the requirements for the Government-wide Strategic Solutions (GSS) for laptops and monitors.
Inpixon won the 2017 IoT Security Excellence Award.
$INPX filed an extension to stay at NASDAQ for 180 day for the first time -it will be granted Bullish STRONG BUY =Revenue increased
$INPX filed annexation for stay at NASDAQ for 180 day for the first time -it will be granted Revenue up Webcast
http://78449.choruscall.com/dataconf/productusers/inpx/mediaframe/18984/indexr.html
BUY-BUY-BUY=PRICE WILL GONG MONDAY UP to $0.89 -$1.19 a share Bullish
STRONG SELL ALERT -INVESTIGATION STARTED= I DID SOLD ALL SHARES
BUY ALERT NEWS- REVENUE UP 69% FDA REVUE COMING UP-Inpixon (INPX), a leading indoor positioning and data analytics company, today announced that it will issue Third Quarter 2017 financial results for the period ended September 30, 2017, and provide an update on corporate developments at 4:05pm eastern time on Monday, November 20, 2017.
Management will host a conference call on Monday, November 20, 2017, at 4:30pm Eastern Time to review financial results and corporate highlights. Following management’s formal remarks, there will be a question and answer session.
To listen to the conference call, interested parties within the U.S. should call 1-844-824-3831. International callers should call +1-412-317-5141. All callers should ask for the Inpixon conference call. The conference call will also be available through a live webcast, which can be accessed at http://client.irwebkit.com/inpixon/events.
A replay of the call will be available approximately one hour after the end of the call through December 20, 2017. The replay can be accessed via Inpixon’s website or by dialing 1-877-344-7529 (U.S.) or +1-412-317-0088 (international). The replay conference playback code is 10114477.
https://finance.yahoo.com/news/inpixon-announce-third-quarter-2017-143000236.html
BUY-BUY-BUY=PRICE MONDAY WILL GO UP to $0.89 -$1.19 a share
STRONG BUY =Revenue incrised 69% new contract on the way Bullish
$AKER STRONG BUY - REVENUE UP ONLY WAY SHARES GOING UP
BUY ALERT NEWS-Goldman Sachs by 595% Increased Position in Cytrx Corp
https://www.thecerbatgem.com/2017/11/15/cytrx-corporation-cytr-position-increased-by-goldman-sachs-group-inc.html
BUY ALERT NEWS CytRx Corporation (CYTR) Position Increased by Goldman Sachs Group Inc.
November 15th, 2017 - By Doug Wharley - 0 comments
CytRx Corporation logoGoldman Sachs Group Inc. boosted its stake in CytRx Corporation (NASDAQ:CYTR) by 795.0% during the 2nd quarter,
https://www.thecerbatgem.com/2017/11/15/cytrx-corporation-cytr-position-increased-by-goldman-sachs-group-inc.html
BUY ALERT-Today (CYTR) will receive it qualify for Nasdaq compliance =opening $2.10 + Bullish-Weeeeeeeeeeeeeee!
TIME TO BUY MORE SHARES
TIME TO BUY MORE SHARES
TIME TO BUY MORE SHARES
BUY ALERT- Today last 10th day over $1.+ Nasdaq compliance =opening $2.10 +
BUY Alert News ! LOS ANGELES, Nov. 13, 2017 /PRNewswire/ -- CytRx today will continue to provide updates on the progress of both aldoxorubicin (by its licensee NantCell) and to meet with certain new prospective shareholders.
hhttps://www.prnewswire.com/news-releases/cytrx-corporation-provides-business-update-and-announces-new-shareholder-initiatives-300554415.html
BUY Alert News ! LOS ANGELES, Nov. 13, 2017 /PRNewswire/ -- CytRx today will continue to provide updates on the progress of both aldoxorubicin (by its licensee NantCell) and to meet with certain new prospective shareholders.
hhttps://www.prnewswire.com/news-releases/cytrx-corporation-provides-business-update-and-announces-new-shareholder-initiatives-300554415.html
$CYTR Nasdaq compliance should be officially filed by November 15, 2017 ,.
10 days over strait closing price $1.00 coming at 4 p.m, by 14 November 2017, needed for Nasdaq compliance should be officially filed by November 15, 2017 ,that is is correct Moderator ? Please reply.
$CYTR BUY SHARS NOW OR IT WILL BE TO LATE FOR YOU TO MAKE MONEY SHARES WILL GO TO $4.50 AFTER NASDAQ COMPPLANCE
THANK YOU FOR LET ME TO BUY YOUR SHARES SO CHIP . TIME TO BUY MORE WEEEEEEEEEEEEEEEEE! Bullish
BUY-BUY-BUY=Over $50 million Cash on hand diluted net loss per share $(0.19) v $(0.80) (CYTR) HAS 126 patents approved with FDA . SELLS INCREASED IN EUROPE -JAPAN , GERMANY , ENGLAND -IRELAND AND FRANCE
JUST SHARES WILL REACH A SKY .
STRONG BUY=Over $50 million Cash on hand diluted net loss per share
$(0.19) v.$(0.80)Bullish
CYTR has more cash than their current $50 million in the market cap! cancer medicine! before NDA!
(CYTR a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has informed the Company that it plans to submit Investigational New Drug (IND) applications combining aldoxorubicin with its immunotherapy protocols for clinical trials addressing patients diagnosed with Pancreatic and Breast cancer.
The planned clinical trials will enroll patients with cancers that are no longer responding, or never responded, to standard therapy and have progressed. The clinical trials will employ an adaptive design which will allow for expansion of treatment cohorts and modification of patient treatments based on tumor profiling and individual patient responses over time.
"The inclusion of aldoxorubicin in NantCell's upcoming pending IND filings is important validation of its potential ability to provide benefit for patients with advanced-stage, difficult to treat cancers," commented Steven A. Kriegsman, CytRx's Chairman and Chief Executive Officer. "These planned trials allow for the continued development of aldoxorubicin in patient populations with great needs for transformation in cancer care."
https://ih.advfn.com/p.php?pid=nmona&article=75849080
LOS ANGELES, Oct. 12, 2017 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has informed the Company that it plans to submit Investigational New Drug (IND) applications combining aldoxorubicin with its immunotherapy protocols for clinical trials addressing patients diagnosed with Pancreatic and Breast cancer.
The planned clinical trials will enroll patients with cancers that are no longer responding, or never responded, to standard therapy and have progressed. The clinical trials will employ an adaptive design which will allow for expansion of treatment cohorts and modification of patient treatments based on tumor profiling and individual patient responses over time.
"The inclusion of aldoxorubicin in NantCell's upcoming pending IND filings is important validation of its potential ability to provide benefit for patients with advanced-stage, difficult to treat cancers," commented Steven A. Kriegsman, CytRx's Chairman and Chief Executive Officer. "These planned trials allow for the continued development of aldoxorubicin in patient populations with great needs for transformation in cancer care."
About CytRx Corporation
CytRx Corporation is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. Aldoxorubicin, CytRx's most advanced drug conjugate, is an improved version of the widely used chemotherapeutic agent doxorubicin and has been out-licensed to NantCell, Inc. CytRx is also rapidly expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies.
About NantCell, Inc.
NantCell, an entity controlled by Dr. Patrick Soon-Shiong, is an immuno-oncology company focused on the discovery of innovative antibody, T cell and NK cell based treatments by developing molecularly targeted therapeutics, based on the proteomic profile of the patient's tumor, independent of the cancer's anatomical type.
NantCell's mission is to make obsolete the standard method of clinical trial design of "trial and error" and replace it with a level of quantitative predictability based on both the genomic and proteomic profile performed a priori. The Company will tap into comprehensive "omic" analytic tools and "big data" generated from supercomputing to develop molecularly designed drugs in this era of genomics and proteomics and identify patients and their tumor signature at the most granular cellular, DNA and protein levels. Patients entering clinical trials would be identified after a comprehensive "omic" analysis from tissue to cell to DNA to RNA to protein to peptide to drug, and tested based on this molecular profile to maximize clinical outcome and minimize side effects. Through these integrated diagnostic methods, the company is pursuing the vision of treating the biology of cancer rather than the anatomy, and drive the immune system inherited by all to defeat cancer. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter @Dr.PatSoonShiong.
Forward-Looking Statements
This press release contains forward-looking statements. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks and uncertainties relating to plans for regaining compliance with the NASDAQ rules and higher share price of our common stock; the ability of NantCell, Inc., to obtain regulatory approval for its products that use aldoxorubicin; the ability of NantCell, Inc., to manufacture and commercialize products or therapies that use aldoxorubicin; the amount, if any, of future milestone and royalty payments that we may receive from NantCell, Inc.; our ability to develop new ultra-high potency drug candidates based on our LADRTM technology platform; and other risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original content:http://www.prnewswire.com/news-releases/cytrx-corporation-highlights-inclusion-of-aldoxorubicin-in-pending-upcoming-clinical-trial-submissions-planned-by-licensee-nantcell-inc-300535444.html
SOURCE CytRx Corporation
Copyright 2017 PR Newswire
https://ih.advfn.com/p.php?pid=nmona&article=75849080
FDA approves Gilead cancer gene therapy; price set at $373,000
https://www.reuters.com/article/us-gilead-sciences-fda/fda-approves-gilead-cancer-gene-therapy-price-set-at-373000-idUSKBN1CN35H